undamentalytics Newsletter
Sign in

Puma Biotechnology, Inc. cash flow statement

In fiscal 2025, Puma Biotechnology, Inc.'s operations generated $41.8m of cash; it spent $71,000 on capital projects, leaving free cash flow of $41.7m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−172−2422121−1627394241
Depreciation and amortisation3781011101212118
Stock-based pay109875737331210877
Capital spending000000000−0
Free cash flow−173−2522121−1627394241
Free cash flow after stock pay−282−111−35−36−12−2817313534

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: IDYA vs PBYIANAB vs PBYIPBYI vs RYTMAKBA vs PBYI

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Puma Biotechnology, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Puma Biotechnology, Inc.